MiniMed Group (NASDAQ:MMED) Reaches New 1-Year Low – Time to Sell?

MiniMed Group Inc (NASDAQ:MMED) hit a new 52-week low on Friday . The stock traded as low as $12.80 and last traded at $12.9250, with a volume of 92965 shares traded. The stock had previously closed at $13.63.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Morgan Stanley assumed coverage on MiniMed Group in a research note on Tuesday, March 31st. They set an “overweight” rating and a $19.00 price objective on the stock. Evercore assumed coverage on MiniMed Group in a research note on Tuesday, March 31st. They set an “outperform” rating and a $20.00 price objective on the stock. William Blair initiated coverage on MiniMed Group in a research note on Tuesday, March 31st. They set an “outperform” rating on the stock. BTIG Research initiated coverage on MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $25.00 target price for the company. Finally, The Goldman Sachs Group initiated coverage on MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $24.00 target price for the company. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.45.

MiniMed Group Trading Down 3.3%

MiniMed Group (NASDAQ:MMED) last announced its quarterly earnings results on Friday, April 17th. The company reported $999.00 earnings per share (EPS) for the quarter.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.